Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Novartis receives SMC approval for early breast cancer treatment

November 11, 2025
Research and Development Novartis, Scottish Medicines Consortium, breast cancer, nhs scotland

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval for use within NHS Scotland …

News
drug-trials

Novartis candidate for Sjögren’s disease presents positive results

August 15, 2025
Research and Development Immunology, Novartis, Sjögren’s disease, US Food and Drug Administration, clinical trial

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 – evaluating ianalumab in adults …

News
Mosquito image

First malaria medicine for infants under 4.5kg receives approval

July 9, 2025
Medical Communications, Research and Development Coartem Baby, Infections and infestations, Medicines for Malaria Venture, Novartis, Paediatrics, Swissmedic, malaria

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine for newborns and young infants. …

News
researchers

Novartis releases new data across oncology and haematology pipelines

May 21, 2025
Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology

Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …

News

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024
Research and Development Novartis, PeptiDream, Pharmacy, collaboration, drug discovery, peptides

PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.

News

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024
Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …

News
chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

March 5, 2024
Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma (onasmenogene abeparvovec), for the treatment …

News

Novartis to acquire MorphoSys AG for €2.7bn

February 6, 2024
Business Services Novartis, Pharmacy, acquisition, morphosys

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …

News

Calypso Biotech to be acquired by Novartis for $250m

January 8, 2024
Business Services Calypso Biotech, Immunology, Novartis, acquisition

Calypso Biotech has announced that it has entered into an agreement to be acquired by Novartis. The company’s shareholders will …

News

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023
Medical Communications FDA, Fabhalta, Haematology, Novartis, PNH

Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as the first oral monotherapy for …

News

Ionis and Novartis partner for CVD treatment programme

August 4, 2023
Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …

News
kidney

Novartis acquires Chinook Therapeutics for $3.5bn

June 12, 2023
Mergers and Acquisitions Chinook Therapeutics, Nephrology, Novartis, kidney disease, pharma

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based biopharmaceutical company Chinook Therapeutics for …

News

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

April 27, 2023
Business Services CHMP, Cosentyx, Dermatology, Novartis

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …

News
Press release
pm_society

AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

September 20, 2021
Sales and Marketing AstraZeneca, Klarify, Novartis, PM Society Awards, havas life medicom

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the 12th PM Society Digital Awards …

News

Novartis announce digital collaboration with HPE

June 24, 2021
AI, HPE, Novartis

Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate its use of data and …

News
The Gateway to Local Adoption Series

Latest content

Molnlycke donates risk prediction patent to SKF’s digital patent platform

November 14, 2025

Study finds at-home brain stimulation therapies reduce depression relapse rate

November 14, 2025

Smurfit Westrock unveils new clinical packaging facility at Dublin Airport

November 13, 2025

EVerZom enters research and licensing agreement with GENFIT

November 13, 2025

University of Birmingham scientists develop new MRI contrast agent

November 12, 2025